Another factor influencing the rating is the uncertainty surrounding Novavax’s pipeline developments, particularly the phase 3 CIC program, which has faced delays due to a clinical hold by the FDA.

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Our Second Value Driver is Novavax's late-stage pipeline. Our late-stage pipeline is comprised of our COVID-19 influenza ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Well-positioned with proven technology, pipeline assets, commercial execution, and a focus on corporate development, Novavax’s platform seems to stand it in good stead for its desired future.

The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have ... Global Clingwrap Machine Market was... Novavax, Inc. , a global company ...

The Company's clinical-stage product pipeline includes VELDONA ® human and animal oral ... Global Clingwrap Machine Market was... Novavax, Inc. , a global company advancing protein-based vaccines with ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Inovio Pharmaceuticals Inc. 0.36% $143.32M ...